Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
September 30, 2026 265.03M
June 30, 2026 -0.014M
March 31, 2026 -0.015M
December 31, 2025 -0.015M
September 30, 2025 -0.007M
June 30, 2025 -0.034M
March 31, 2025 -0.087M
December 31, 2024 -0.132M
September 30, 2024 -0.002M
June 30, 2024 -0.003M
March 31, 2024 -0.004M
December 31, 2023 82.66M
September 30, 2023 -0.047M
June 30, 2023 -0.005M
March 31, 2023 -0.217M
December 31, 2022 0.208M
September 30, 2022 -0.026M
June 30, 2022 -0.061M
March 31, 2022 1.532M
December 31, 2021 -0.038M
Date Value
September 30, 2021 -33.56M
June 30, 2021 -0.129M
March 31, 2021 73.50M
December 31, 2020 7.98M
September 30, 2020 0.082M
June 30, 2020 53.61M
March 31, 2020 0.14M
December 31, 2019 20.00M
September 30, 2019 27.94M
June 30, 2019 0.002M
March 31, 2019 0.016M
December 31, 2018 0.002M
September 30, 2018 0.488M
June 30, 2018 0.034M
March 31, 2018 125.39M
December 31, 2017 -0.87M
September 30, 2017 50.36M
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.00

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Cypherpunk Technologies, Inc. 57.26M
Cue Biopharma, Inc. 50.63M
Faeth Therapeutics, Inc. 0.104M
Indaptus Therapeutics, Inc. 20.30M
Pyxis Oncology, Inc. 38.58M